Why Axsome Stock Has Doubled In Nine Months

Investors watching Axsome Therapeutics have seen the stock more than double in nine months, riding a wave of FDA approvals and a pipeline that promises more blockbuster CNS drugs. The company behind the antidepressant Auvelity and narcolepsy treatment Sunosi has transformed from a speculative biotech into a revenue-generating powerhouse, with shares surging from under $50 to over $100 since October 2025. Axsome Therapeutics, based in New York City, has achieved this meteoric rise by executing on its central nervous system franchise. Auvelity, approved in 2022 for major depressive disorder, has captured significant market share thanks to its rapid onset and novel mechanism. The drug generated $450 million in 2025 sales, exceeding analyst expectations. Meanwhile, Sunosi continues to hold its ground in the narcolepsy and obstructive sleep apnea market, contributing steady revenue. The stock's rally accelerated in late 2025 when Axsome reported positive Phase 3 data for AXS-05 in Alzheimer's disease agitation, a condition with no approved therapies. The trial showed a 40% reduction in agitation episodes compared to placebo, opening a potential multi-billion-dollar market. The company also expanded its pipeline with AXS-12 for narcolepsy type 1 and AXS-14 for fibromyalgia, both advancing through later-stage trials. Wall Street analysts have responded by raising price targets, with several now above $150 a share. The bullish narrative is built on Axsome's ability to commercialize drugs in underserved CNS indications, where big pharma has often failed. The company's internal sales force and patient support programs have driven Auvelity's rapid uptake. CEO Herriot Tabuteau has emphasized a 'precision neurology' approach, leveraging biomarkers to identify patients most likely to respond. This strategy reduces the risk of failed trials and improves the odds of regulatory success. However, risks remain: competitors like Sage Therapeutics and Biogen are targeting similar indications, and Axsome faces patent challenges on its core products. The stock's forward price-to-earnings ratio of 35x is not cheap, reflecting high expectations. The next catalysts include Phase 2 data for AXS-05 in bipolar depression later this year and potential FDA approval for AXS-12 in narcolepsy by mid-2027. Analysts also see a licensing or acquisition scenario as likely if the pipeline continues to deliver. For now, Axsome's ability to turn promise into profit has rewarded early investors, and the trajectory suggests more gains ahead for those willing to hold through volatility.